Jump to content

Psychedelic microdosing

From Wikipedia, the free encyclopedia

Part of a series on
Psychedelia
Arts

Psychedelic film

Culture
Drugs
Experience
History
Law
Related topics

Psychedelic microdosing is a form of drug microdosing in which sub-hallucinogenic doses of serotonergic psychedelics like LSD and psilocybin are taken for claimed cognitive and emotional benefits.[1][2][3]

Uses, research, and effects

[edit]

A variety of perceived benefits of psychedelic microdosing have been anecdotally claimed, such as beneficial effects on mood or well-being, anxiety, cognitive function, creativity, and productivity.[4][5][6][3] In addition, people informally use microdosing to treat psychiatric conditions and it is being formally clinically studied for such purposes.[5][7][8] Examples include for depression,[9] anxiety,[8] obsessive–compulsive disorder (OCD),[8] post-traumatic stress disorder (PTSD),[8] substance misuse,[8] and schizophrenia,[10] among others.[8] There is very little scientific research on microdosing or its effects as of 2024 however and the claimed beneficial effects of microdosing have largely not been scientifically validated.[2][1]

LSD microdosing three times per week was found in a preliminary 2024 randomized controlled trial to increase sleep duration by 24 minutes on average one day after the microdose (but not the same night of the dose).[2][11] This included an increase in duration of REM sleep.[2][11]

Psychedelics and microdosing are being͏͏ investigated͏͏ for potential͏͏ treatment of neurodegenerative disorders like͏͏ Alzheimer's disease.͏͏[12][13] They are also being studied for treatment of depression in people with Alzheimer's disease.[13] Certain psychedelics, like DOI and psilocybin, acting as serotonin 5-HT2A receptor agonists, have been found to have potent anti-inflammatory effects at doses well below those that produce hallucinogenic effects in preclinical research and are being clinically investigated for the potential treatment of inflammatory conditions such as neuroinflammation.[14][15][16][17] The anti-inflammatory effects of psychedelics may be involved in the possible benefits of microdosing.[1][18] LSD microdosing is being clinically studied in the treatment of Alzheimer's disease for its anti-inflammatory effects.[19][20]

The benefits of microdosing may in part or full be a placebo mediated by positive expectancy effects.[21][22][23][24] In people with major depressive disorder, placebos are known to produce substantial reductions in depressive symptoms all on their own and conventional antidepressants barely outperform placebos in clinical trials.[25][26][27] Some researchers have proposed that psychedelics, in general, may be active "super placebos" due to their powerful hallucinogenic effects and cultural associations.[28][29]

Tolerance and tachyphylaxis are known to rapidly develop to the hallucinogenic effects and to other effects of serotonergic psychedelics in both animals and humans.[30][31][32] This is thought to be mediated by rapid serotonin 5-HT2A receptor downregulation that is very slow to recover.[30][31] Tolerance and loss of effect could serve to limit the potential beneficial effects of psychedelic microdosing and this is a phenomenon that has been observed in existing clinical studies.[1][9] More research is needed to further assess this issue.[2]

Dosage and administration

[edit]

LSD and psilocybin, the latter often in the form of psilocybin-containing mushrooms, are the most commonly used psychedelics in microdosing.[33] A microdose is considered to be between approximately one-twentieth to one-tenth of a typical recreational dose.[3][9] Microdoses of psychedelics are 5 to 20 μg for LSD, 1 to 5 mg for psilocybin, 0.1 to 0.5 g of psilocybin-containing mushrooms, and <75 mg for mescaline.[34][35][36][2][19] These psychedelics have perceptible psychedelic effects at minimum doses of 10 to 20 μg for LSD, 3 to 5 mg psilocybin, 0.5 g psilocybin-containing mushrooms, and 100 mg mescaline.[34][35][36][2]

Side effects

[edit]

Side effects of psychedelic microdosing with LSD or psilocybin may include increased blood pressure, anxiety, cognitive impairment, and physiological discomfort.[37][6] The side effects of microdosing are generally infrequent, mild, dose-dependent, and short-lasting.[37][6]

Long-term toxicity

[edit]

Psychedelics, including LSD, psilocybin, dimethyltryptamine (DMT), mescaline, and many others,[38][39] are potent serotonin 5-HT2B receptor agonists in addition to the serotonin 5-HT2A receptor agonism that mediates their hallucinogenic effects.[40][41][42][43] Long-term use of potent serotonin 5-HT2B receptor agonists like fenfluramine, methysergide, ergotamine, cabergoline, pergolide, and MDMA is known to produce serious organ toxicity including cardiac fibrosis, valvulopathy, and pulmonary hypertension.[44][45][46][47][48] Conversely, certain other serotonin 5-HT2B receptor agonists, such as guanfacine, ropinirole, and oxymetazoline, have not been associated with such toxicities, perhaps due to factors like biased agonism and/or inadequate potency or exposure.[44][48][49] Due to potent serotonin 5-HT2B receptor agonism, long-term use of psychedelics, for instance microdosing, might produce heart and other organ toxicity.[43][40][41][42] Conversely, infrequent macrodoses of psychedelics are thought to be safe.[40][42][50]

The risk of cardiac valvulopathy and toxicity with long-term use of psychedelics is, aside from the case of MDMA, theoretical and has largely not been assessed or demonstrated in animals or humans.[40][41][42][50] It is notable in this regard that findings on the serotonin 5-HT2B receptor agonism of psychedelics including LSD, psilocybin, mescaline, and dimethyltryptamine (DMT) are conflicting, with some studies finding them to be potent serotonin 5-HT2B receptor agonists and others finding them to be very weak or negligible serotonin 5-HT2B receptor agonists, depending on the study and assay.[38][50][39] The cardiac toxicity of serotonin 5-HT2B receptor activation has been specifically linked to extracellular regulating kinase 2 (ERK2) signaling and not necessarily to other downstream signaling pathways.[42][50] LSD has been found to have low activity on a valvulopathogenic ERK2 serotonin 5-HT2B receptor agonism readout relative to known or suspected valvopathogens like norfenfluramine, pergolide, methylergonovine (methylergometrine), ergonovine (ergometrine), cabergoline, dihydroergotamine, and ergotamine.[42][50] This was in terms of both activational potency (EC50Tooltip half-maximal effective concentration = 110 nM vs. 1.0–20 nM, respectively) and efficacy (EmaxTooltip half-maximal effective concentration = 39% vs. 53–79%, respectively).[50] Conversely, other psychedelics like psilocin, DMT, and mescaline have not been assessed in terms of this assay as of 2022.[50] However, other research suggests that the toxicity may not be specifically or exclusively dependent on ERK2 signaling.[42] More research is needed to determine whether long-term frequent use of psychedelics, including microdosing, may cause cardiac valvulopathy and other related toxicities.[43][40][41][42]

Selective serotonin 5-HT2A receptor agonists that do not activate the serotonin 5-HT2B receptor or other serotonin receptors, such as 25CN-NBOH, DMBMPP, and LPH-5, have been developed and are being studied.[51][52] Selective serotonin 5-HT2A receptor agonists are expected to avoid the cardiac risks of serotonin 5-HT2B receptor activation.[52] In addition, selective serotonin 5-HT2B receptor antagonists, including peripherally selective drugs like VU0530244, are being investigated and developed for potential medical use.[46][53][54] Selective serotonin 5-HT2B receptor antagonism has been found to fully prevent the cardiotoxicity of dexnorfenfluramine in animal studies, but clinical studies are needed.[55][56]

Pharmacology

[edit]

The clinical pharmacodynamics and pharmacokinetics of microdosed LSD have been studied.[2][57][20]

History

[edit]

According to psychedelic researcher Matthew J. Baggott in 2023, the first documented instance of psychedelic microdosing may be the Grateful Dead's use of low and sub-psychedelic doses of DOM as a mild stimulant in the late 1960s.[58] However, studies of the effects of very low doses of psychedelics date back as early as 1955.[3][59] Albert Hofmann first mentioned psychedelic microdosing and possible therapeutic benefits of the intervention like euphoria and antidepressant effects in a 1976 High Times interview.[60][61] He is said to have taken microdoses of LSD for most of the later years of his life.[62] James Fadiman was responsible for introducing the modern paradigm and phenomenon of psychedelic microdosing, which had previously been largely unknown, with his 2011 book The Psychedelic Explorer's Guide.[63][60][64] Ayelet Waldman additionally helped to popularize microdosing with her 2017 book A Really Good Day: How Microdosing Made a Mega Difference in My Mood, My Marriage, and My Life.[63][65] There has been a dramatic increase in interest in psychedelic microdosing as well as scientific research into the practice since 2018.[63]

Society and culture

[edit]

Psychedelic microdosing is frequently discussed on online forums such as the r/microdosing community on Reddit.[1][6][66]

See also

[edit]

References

[edit]
  1. ^ a b c d e Kuypers KP, Ng L, Erritzoe D, Knudsen GM, Nichols CD, Nichols DE, Pani L, Soula A, Nutt D (September 2019). "Microdosing psychedelics: More questions than answers? An overview and suggestions for future research". J Psychopharmacol. 33 (9): 1039–1057. doi:10.1177/0269881119857204. PMC 6732823. PMID 31303095.
  2. ^ a b c d e f g h Murphy RJ, Muthukumaraswamy S, de Wit H (May 2024). "Microdosing Psychedelics: Current Evidence From Controlled Studies". Biol Psychiatry Cogn Neurosci Neuroimaging. 9 (5): 500–511. doi:10.1016/j.bpsc.2024.01.002. PMID 38280630.
  3. ^ a b c d Polito V, Liknaitzky P (August 2022). "The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field". Neurosci Biobehav Rev. 139: 104706. doi:10.1016/j.neubiorev.2022.104706. PMID 35609684.
  4. ^ Wong A, Raz A (October 2022). "Microdosing with classical psychedelics: Research trajectories and practical considerations". Transcult Psychiatry. 59 (5): 675–690. doi:10.1177/13634615221129115. PMID 36317302.
  5. ^ a b Totomanova I, Haijen EC, Hurks PP, Ramaekers JG, Kuypers KP (2025). "Potential therapeutic effects of psychedelics in small doses: Is there a role for microdosing in psychiatry?". International Review of Neurobiology. Elsevier. doi:10.1016/bs.irn.2025.03.002. Retrieved 27 April 2025.
  6. ^ a b c d Bornemann J (2020). "The Viability of Microdosing Psychedelics as a Strategy to Enhance Cognition and Well-being - An Early Review". J Psychoactive Drugs. 52 (4): 300–308. doi:10.1080/02791072.2020.1761573. PMID 32362269.
  7. ^ Kuypers KP (2024). "Microdosing Psychedelics as a Promising New Pharmacotherapeutic". Modern CNS Drug Discovery. Cham: Springer Nature Switzerland. pp. 407–436. doi:10.1007/978-3-031-61992-2_26. ISBN 978-3-031-61991-5. Retrieved 27 April 2025.
  8. ^ a b c d e f Irizarry R, Winczura A, Dimassi O, Dhillon N, Minhas A, Larice J (November 2022). "Psilocybin as a Treatment for Psychiatric Illness: A Meta-Analysis". Cureus. 14 (11): e31796. doi:10.7759/cureus.31796. PMC 9779908. PMID 36569662.
  9. ^ a b c Kuypers KP (2020). "The therapeutic potential of microdosing psychedelics in depression". Ther Adv Psychopharmacol. 10: 2045125320950567. doi:10.1177/2045125320950567. PMC 7457631. PMID 32922736.
  10. ^ Wolf G, Singh S, Blakolmer K, Lerer L, Lifschytz T, Heresco-Levy U, Lotan A, Lerer B (January 2023). "Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation". Mol Psychiatry. 28 (1): 44–58. doi:10.1038/s41380-022-01832-z. PMID 36280752.
  11. ^ a b Allen N, Jeremiah A, Murphy R, Sumner R, Forsyth A, Hoeh N, Menkes DB, Evans W, Muthukumaraswamy S, Sundram F, Roop P (April 2024). "LSD increases sleep duration the night after microdosing". Transl Psychiatry. 14 (1): 191. doi:10.1038/s41398-024-02900-4. PMC 11018829. PMID 38622150.
  12. ^ Vann Jones SA, O'Kelly A (2020). "Psychedelics as a Treatment for Alzheimer's Disease Dementia". Front Synaptic Neurosci. 12: 34. doi:10.3389/fnsyn.2020.00034. PMC 7472664. PMID 32973482.
  13. ^ a b Pilozzi A, Foster S, Mischoulon D, Fava M, Huang X (August 2023). "A Brief Review on the Potential of Psychedelics for Treating Alzheimer's Disease and Related Depression". Int J Mol Sci. 24 (15): 12513. doi:10.3390/ijms241512513. PMC 10419627. PMID 37569888.
  14. ^ Nichols DE, Johnson MW, Nichols CD (February 2017). "Psychedelics as Medicines: An Emerging New Paradigm". Clin Pharmacol Ther. 101 (2): 209–219. doi:10.1002/cpt.557. PMID 28019026.
  15. ^ Flanagan TW, Nichols CD (2022). "Psychedelics and Anti-inflammatory Activity in Animal Models". Disruptive Psychopharmacology. Current Topics in Behavioral Neurosciences. Vol. 56. pp. 229–245. doi:10.1007/7854_2022_367. ISBN 978-3-031-12183-8. PMID 35546383.
  16. ^ Nichols CD (November 2022). "Psychedelics as potent anti-inflammatory therapeutics". Neuropharmacology. 219: 109232. doi:10.1016/j.neuropharm.2022.109232. PMID 36007854.
  17. ^ Flanagan TW, Nichols CD (August 2018). "Psychedelics as anti-inflammatory agents" (PDF). Int Rev Psychiatry. 30 (4): 363–375. doi:10.1080/09540261.2018.1481827. PMID 30102081.
  18. ^ Kinderlehrer DA (2025). "Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity". Neuropsychiatr Dis Treat. 21: 141–155. doi:10.2147/NDT.S500337. PMC 11787777. PMID 39897712.
  19. ^ a b Kozlowska U, Nichols C, Wiatr K, Figiel M (July 2022). "From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders". J Neurochem. 162 (1): 89–108. doi:10.1111/jnc.15509. PMID 34519052. One dosing method of psychedelics is the use of so called "microdoses"—very low concentrations of various psychedelics that do not reach the threshold of perceivable behavioral effects. This is usually 10% of active recreational doses (e.g., 10–15 µg of LSD, or 0.1–0.3 g of dry "magic mushrooms") taken up to three times per week.
  20. ^ a b Family N, Maillet EL, Williams LT, Krediet E, Carhart-Harris RL, Williams TM, Nichols CD, Goble DJ, Raz S (March 2020). "Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers". Psychopharmacology (Berl). 237 (3): 841–853. doi:10.1007/s00213-019-05417-7. PMC 7036065. PMID 31853557.
  21. ^ Polito V, Liknaitzky P (August 2024). "Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research". J Psychopharmacol. 38 (8): 701–711. doi:10.1177/02698811241254831. PMC 11311906. PMID 38877715.
  22. ^ Szigeti B, Heifets BD (May 2024). "Expectancy Effects in Psychedelic Trials". Biol Psychiatry Cogn Neurosci Neuroimaging. 9 (5): 512–521. doi:10.1016/j.bpsc.2024.02.004. PMID 38387698.
  23. ^ Ona G, Bouso JC (December 2020). "Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: A systematic review". Neurosci Biobehav Rev. 119: 194–203. doi:10.1016/j.neubiorev.2020.09.035. PMID 33031815.
  24. ^ Kaertner LS, Steinborn MB, Kettner H, Spriggs MJ, Roseman L, Buchborn T, Balaet M, Timmermann C, Erritzoe D, Carhart-Harris RL (January 2021). "Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing". Sci Rep. 11 (1): 1941. doi:10.1038/s41598-021-81446-7. PMC 7820236. PMID 33479342.
  25. ^ Kirsch I (2019). "Placebo Effect in the Treatment of Depression and Anxiety". Front Psychiatry. 10: 407. doi:10.3389/fpsyt.2019.00407. PMC 6584108. PMID 31249537.
  26. ^ Moncrieff J, Kirsch I (July 2005). "Efficacy of antidepressants in adults". BMJ. 331 (7509): 155–157. doi:10.1136/bmj.331.7509.155. PMC 558707. PMID 16020858.
  27. ^ Munkholm K, Paludan-Müller AS, Boesen K (June 2019). "Considering the methodological limitations in the evidence base of antidepressants for depression: a reanalysis of a network meta-analysis". BMJ Open. 9 (6): e024886. doi:10.1136/bmjopen-2018-024886. PMC 6597641. PMID 31248914.
  28. ^ Dupuis D, Veissière S (October 2022). "Culture, context, and ethics in the therapeutic use of hallucinogens: Psychedelics as active super-placebos?". Transcult Psychiatry. 59 (5): 571–578. doi:10.1177/13634615221131465. PMID 36263513.
  29. ^ van Elk M, Yaden DB (September 2022). "Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review". Neurosci Biobehav Rev. 140: 104793. doi:10.1016/j.neubiorev.2022.104793. hdl:1887/3515020. PMID 35878791. In addition, the strong prior expectations that many people have about psychedelics directly contribute to the psychedelic experience and as a consequence it has been suggested that psychedelics may act as a 'super-placebo' (Hartogsohn, 2016). Specifically, strong prior expectations (e.g., that a specific intervention will likely trigger a mystical experience) will increase the likelihood of having e.g., a mystical-type experience (Maij et al., 2019), and this placebo-effect is further boosted by the psychedelic-induced suggestibility.
  30. ^ a b Halberstadt AL (January 2015). "Recent advances in the neuropsychopharmacology of serotonergic hallucinogens". Behav Brain Res. 277: 99–120. doi:10.1016/j.bbr.2014.07.016. PMC 4642895. PMID 25036425.
  31. ^ a b Nichols DE (February 2004). "Hallucinogens". Pharmacol Ther. 101 (2): 131–181. doi:10.1016/j.pharmthera.2003.11.002. PMID 14761703.
  32. ^ de la Fuente Revenga M, Jaster AM, McGinn J, Silva G, Saha S, González-Maeso J (August 2022). "Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice". ACS Chem Neurosci. 13 (16): 2436–2448. doi:10.1021/acschemneuro.2c00170. PMC 10411500. PMID 35900876.
  33. ^ Preller KH (November 2019). "The Effects of Low Doses of Lysergic Acid Diethylamide in Healthy Humans: Demystifying the Microdosing of Psychedelics". Biological Psychiatry. 86 (10): 736–737. doi:10.1016/j.biopsych.2019.08.021. PMID 31648681. S2CID 204800273.
  34. ^ a b Lo DF, Zia H, Rajkumar P, Thakur A, O'Donnell H (January 2024). "Modern Psychedelic Microdosing Research on Mental Health: A Systematic Review". Prim Care Companion CNS Disord. 26 (1). doi:10.4088/PCC.23r03581. PMID 38228068.
  35. ^ a b Holze F, Singh N, Liechti ME, D'Souza DC (May 2024). "Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile". Biol Psychiatry Cogn Neurosci Neuroimaging. 9 (5): 472–489. doi:10.1016/j.bpsc.2024.01.007. PMID 38301886.
  36. ^ a b Liechti ME, Holze F (2022). "Dosing Psychedelics and MDMA". Disruptive Psychopharmacology. Curr Top Behav Neurosci. Vol. 56. pp. 3–21. doi:10.1007/7854_2021_270. ISBN 978-3-031-12183-8. PMID 34734392.
  37. ^ a b Modzelewski S, Stankiewicz A, Waszkiewicz N, Łukasiewicz K (June 2025). "Side effects of microdosing lysergic acid diethylamide and psilocybin: A systematic review of potential physiological and psychiatric outcomes". Neuropharmacology. 271: 110402. doi:10.1016/j.neuropharm.2025.110402. PMID 40058407.
  38. ^ a b Luethi D, Liechti ME (2021). "Drugs of Abuse Affecting 5-HT2B Receptors". 5-HT2B Receptors. Vol. 35. Cham: Springer International Publishing. pp. 277–289. doi:10.1007/978-3-030-55920-5_16. ISBN 978-3-030-55919-9. Retrieved 27 April 2025.
  39. ^ a b Wallach J, Cao AB, Calkins MM, Heim AJ, Lanham JK, Bonniwell EM, Hennessey JJ, Bock HA, Anderson EI, Sherwood AM, Morris H, de Klein R, Klein AK, Cuccurazzu B, Gamrat J, Fannana T, Zauhar R, Halberstadt AL, McCorvy JD (December 2023). "Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential". Nat Commun. 14 (1): 8221. doi:10.1038/s41467-023-44016-1. PMC 10724237. PMID 38102107.
  40. ^ a b c d e Tagen M, Mantuani D, van Heerden L, Holstein A, Klumpers LE, Knowles R (September 2023). "The risk of chronic psychedelic and MDMA microdosing for valvular heart disease". J Psychopharmacol. 37 (9): 876–890. doi:10.1177/02698811231190865. PMID 37572027.
  41. ^ a b c d Wsół A (December 2023). "Cardiovascular safety of psychedelic medicine: current status and future directions". Pharmacol Rep. 75 (6): 1362–1380. doi:10.1007/s43440-023-00539-4. PMC 10661823. PMID 37874530.
  42. ^ a b c d e f g h Rouaud A, Calder AE, Hasler G (March 2024). "Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins". J Psychopharmacol. 38 (3): 217–224. doi:10.1177/02698811231225609. PMC 10944580. PMID 38214279.
  43. ^ a b c McIntyre RS (2023). "Serotonin 5-HT2B receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents". Expert Opin Drug Saf. 22 (10): 881–883. doi:10.1080/14740338.2023.2248883. PMID 37581427.
  44. ^ a b Elangbam CS (October 2010). "Drug-induced valvulopathy: an update". Toxicol Pathol. 38 (6): 837–848. doi:10.1177/0192623310378027. PMID 20716786.
  45. ^ Hutcheson JD, Setola V, Roth BL, Merryman WD (November 2011). "Serotonin receptors and heart valve disease--it was meant 2B". Pharmacol Ther. 132 (2): 146–157. doi:10.1016/j.pharmthera.2011.03.008. PMC 3179857. PMID 21440001.
  46. ^ a b Bender AM, Parr LC, Livingston WB, Lindsley CW, Merryman WD (August 2023). "2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery". J Med Chem. 66 (16): 11027–11039. doi:10.1021/acs.jmedchem.3c01178. PMC 11073569. PMID 37584406.
  47. ^ Rothman RB, Baumann MH (May 2009). "Serotonergic drugs and valvular heart disease". Expert Opin Drug Saf. 8 (3): 317–329. doi:10.1517/14740330902931524. PMC 2695569. PMID 19505264.
  48. ^ a b Huang XP, Setola V, Yadav PN, Allen JA, Rogan SC, Hanson BJ, Revankar C, Robers M, Doucette C, Roth BL (October 2009). "Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment". Mol Pharmacol. 76 (4): 710–722. doi:10.1124/mol.109.058057. PMC 2769050. PMID 19570945.
  49. ^ Dumotier BM, Urban L (2024). "Preclinical mitigation of 5-HT2B agonism-related cardiac valvulopathy revisited". J Pharmacol Toxicol Methods. 128: 107542. doi:10.1016/j.vascn.2024.107542. PMID 39032441.
  50. ^ a b c d e f g Roihuvuo E (31 January 2022). "Classical psychedelics and NBOMes as serotonin 2B receptor agonists: Valvulopathogenic signaling pathways and cardiac safety concerns". Itä-Suomen yliopisto. Retrieved 27 April 2025.
  51. ^ Duan W, Cao D, Wang S, Cheng J (January 2024). "Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants". Chem Rev. 124 (1): 124–163. doi:10.1021/acs.chemrev.3c00375. PMID 38033123.
  52. ^ a b Peplow M (2024). "Next-generation psychedelics: should new agents skip the trip?". Nature Biotechnology. 42 (6): 827–830. doi:10.1038/s41587-024-02285-1. ISSN 1087-0156. PMID 38831049. Another problem is that some classical psychedelics are also agonists of the 5-HT2B receptor, which is expressed in heart tissue and can cause long-term cardiac problems. Kristensen's company Lophora aims to solve that with its lead compound LPH-5, a phenylethylamine derivative with an extra molecular ring that makes it less flexible. LPH-5 has a 60-fold higher selectivity for 5-HT2A over 5-HT2B.
  53. ^ Padhariya K, Bhandare R, Canney D, Velingkar V (2017). "Cardiovascular Concern of 5-HT2B Receptor and Recent Vistas in the Development of Its Antagonists". Cardiovasc Hematol Disord Drug Targets. 17 (2): 86–104. doi:10.2174/1871529X17666170703115111. PMID 28676029.
  54. ^ Löfdahl A, Tornling G, Wigén J, Larsson-Callerfelt AK, Wenglén C, Westergren-Thorsson G (December 2020). "Pathological Insight into 5-HT2B Receptor Activation in Fibrosing Interstitial Lung Diseases". Int J Mol Sci. 22 (1): 225. doi:10.3390/ijms22010225. PMC 7796180. PMID 33379351.
  55. ^ Dini G, Di Cara G, Ferrara P, Striano P, Verrotti A (2023). "Reintroducing Fenfluramine as a Treatment for Seizures: Current Knowledge, Recommendations and Gaps in Understanding". Neuropsychiatric Disease and Treatment. 19: 2013–2025. doi:10.2147/NDT.S417676. PMC 10543412. PMID 37790801.
  56. ^ Ayme-Dietrich E, Lawson R, Côté F, de Tapia C, Da Silva S, Ebel C, Hechler B, Gachet C, Guyonnet J, Rouillard H, Stoltz J, Quentin E, Banas S, Daubeuf F, Frossard N, Gasser B, Mazzucotelli JP, Hermine O, Maroteaux L, Monassier L (November 2017). "The role of 5-HT2B receptors in mitral valvulopathy: bone marrow mobilization of endothelial progenitors". British Journal of Pharmacology. 174 (22): 4123–4139. doi:10.1111/bph.13981. PMC 5680644. PMID 28806488.
  57. ^ Morse JD, Jeong SH, Murphy RJ, Muthukumaraswamy SD, Sumner RL (April 2025). "Pharmacokinetics and pharmacodynamics of sublingual microdosed lysergic acid diethylamide in healthy adult volunteers". J Psychopharmacol: 2698811251330747. doi:10.1177/02698811251330747. PMID 40251818.
  58. ^ Baggott MJ (1 October 2023). "Learning about STP: A Forgotten Psychedelic from the Summer of Love" (PDF). History of Pharmacy and Pharmaceuticals. 65 (1): 93–116. doi:10.3368/hopp.65.1.93. ISSN 2694-3034. Retrieved 26 January 2025. The Grateful Dead learned they could use small amounts as a stimulant, an effect they used extensively during the recording of the album Aoxomoxoa in 1968 and 1969.143 The use of lower doses of DOM echoed DOET's "psychic energizer" effects and may be the first documented use of subpsychedelic doses of a psychedelic for cognitive enhancement, a practice that is now called microdosing.144
  59. ^ Abramson HA, Kornetsky C, Jarvik ME, Kaufman MR, Ferguson MW (1955). "Lysergic Acid Diethylamide (Lsd-25): Xi. Content Analysis of Clinical Reactions". The Journal of Psychology. 40 (1): 53–60. doi:10.1080/00223980.1955.9712963. ISSN 0022-3980. Retrieved 27 April 2025.
  60. ^ a b Archaic Revival (28 August 2023). "Beyond the Hype: Challenging the Effectiveness of Microdosing Schedules". Tripsitter. Retrieved 27 April 2025. James Fadiman first ignited the microdosing craze with his 2011 book, The Psychedelic Explorer's Guide. Before this book, microdosing was largely unknown — though Albert Hofmann first mentioned the practice in a 1976 High Times article.
  61. ^ Michael Horowitz (July 1976). "Interview: Albert Hofmann". High Times. No. 11. pp. 24–28, 31, 81. High Times: What general medical uses might LSD be marketed for in the future? Hofmann: Very small doses, perhaps 25 micrograms, could be useful as a euphoriant or antidepressant.
  62. ^ Cooke J (16 January 2021). "The Ultimate Guide to Microdosing Psychedelics". Tripsitter. Retrieved 27 April 2025. Albert Hofmann, Ph.D. — the man who invented LSD — took microdoses of the substance for most of the later years of his life. He lived to the ripe old age of 102.
  63. ^ a b c Marks M, Cohen IG, Perez-Reyzin J, Angelatos D (13 January 2025). "Microdosing Psychedelics Under Local, State, and Federal Law". Scholarship Repository. 103: 573. Retrieved 27 April 2025. Despite this history, microdosing, as practiced today, is a relatively new trend that traces its roots to James Fadiman's 2011 book, which contains several case reports from people who report having microdosed. 252 The practice was also popularized by Ayelet Waldman in her autobiographical book, A Really Good Day: How Microdosing Made a Mega Difference in My Mood, My Marriage, and My Life.253 Though people have likely microdosed for centuries in Mexico and elsewhere throughout the world, Fadiman and Waldman brought this mode of psychedelics consumption to a larger audience, garnering the media attention that has perpetuated the trend, and ultimately triggering an explosion of scientific research into microdosing since 2018.254
  64. ^ Fadiman J (18 May 2011). The Psychedelic Explorer's Guide: Safe, Therapeutic, and Sacred Journeys. Simon and Schuster. ISBN 978-1-59477-936-7. Retrieved 27 April 2025.
  65. ^ Waldman A (9 January 2018). A Really Good Day: How Microdosing Made a Mega Difference in My Mood, My Marriage, and My Life. Knopf Doubleday Publishing Group. ISBN 978-1-101-97372-1. Retrieved 27 April 2025.
  66. ^ Pop IA, Gielens E, Kottmann H, Achterberg P (April 2024). "Exploring the discourses around microdosing psychedelics within the r/microdosing online community". Soc Sci Med. 347: 116702. doi:10.1016/j.socscimed.2024.116702. PMID 38520826.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Psychedelic_microdosing&oldid=1289045869"